Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Nutex Health Inc. made false statements and concealed information regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent nature of the conduct [2]. - The company reportedly overstated its remediation efforts regarding material weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [2]. - As a result of these issues, Nutex Health Inc. faced increased risks of failing to file financial reports with the SEC in a timely manner, which overstated its business and financial prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, indicating its expertise in handling complex securities cases [4].

Accessibility StatementSkip Navigation NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nutex Health Inc. ("Nutex" or the "Company") (NASDAQ: NUTX) and certain officers. The class action, filed in the United States District Court for the Southern District of Texas, and docketed under 25- cv- 03999, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nutex securities betwee ...

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Nutex Health Inc. (NASDAQ: NUTX)?Did you purchase your shares between August 8, 2024 and August 14, 2025, inclusive?Did you lose money ...

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Nutex securities between August 8, 2024, and August 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by October 21, 2025 [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Nutex - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls, particularly concerning its relationship with HaloMD, a third-party vendor [5]. - Specific claims include that Nutex engaged in a scheme to defraud insurance companies, leading to unsustainable revenue and improper accounting of stock-based compensation obligations [5]. - The lawsuit asserts that these misrepresentations resulted in overstated business and financial prospects for Nutex, causing investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls, particularly concerning its relationship with HaloMD, a third-party vendor [4]. - Specific claims include that Nutex engaged in fraudulent activities to inflate revenues, overstated its ability to remediate internal control weaknesses, and improperly classified stock-based compensation obligations [4]. - The lawsuit asserts that these misrepresentations led to an overstatement of Nutex's business and financial prospects, resulting in investor damages when the truth was revealed [4].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for violations of federal securities laws, impacting investors who acquired Nutex securities during the specified Class Period from August 8, 2024, to August 14, 2025 [1][2]. Group 1: Allegations Against Nutex - The lawsuit alleges that Nutex and its officers made false and misleading statements regarding the company's financial practices and internal controls [2]. - Specific claims include that Nutex engaged in fraudulent activities through HaloMD, leading to unsustainable revenue and improper accounting of stock-based compensation obligations [2]. - The company is accused of overstating its financial prospects and failing to disclose material weaknesses in its internal controls over financial reporting [2]. Group 2: Impact on Investors - Following the revelation of these allegations, Nutex's common stock experienced a significant decline, resulting in financial losses for investors [3]. - Investors who suffered losses exceeding $50,000 are encouraged to participate in the lawsuit, with a deadline to act as Lead Plaintiff set for October 21, 2025 [3]. Group 3: About the Law Firm - Lowey Dannenberg P.C. is a law firm specializing in representing institutional and individual investors who have suffered financial losses due to corporate fraud and violations of federal securities laws [4]. - The firm has a track record of prosecuting multi-million-dollar lawsuits and has recovered billions for its clients [4].

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Nutex Health Inc. made false statements and concealed information regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to defraud insurance companies [2]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent nature of the conduct [2]. - The company reportedly overstated its remediation of material weaknesses in internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [2]. - As a result of these issues, Nutex Health Inc. faced increased risks of failing to file financial reports with the SEC in a timely manner, and its business and financial prospects were overstated [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][10]. Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2]. - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract excessive reimbursements [2][4]. - The complaint asserts that Nutex's revenue model is unstable and that financial statements misrepresented the company's operations [3]. Group 2: Market Reaction - Following the release of a report by Blue Orca Capital accusing HaloMD of fraud, Nutex's stock dropped over 10%, indicating investor concern [4][5]. - After Nutex delayed its Form 10-Q submission, shares plummeted 16.39% the next day, closing at $92.91 [7]. Group 3: Financial Reporting Issues - The lawsuit highlights misrepresentation in Nutex's financial controls, particularly regarding the classification of stock-based compensation obligations [6]. - On August 21, Nutex disclosed that its Audit Committee found prior financial statements required restatement due to incorrect classification of obligations related to hospital development [8]. Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, arguing that public disclosures were materially misleading [10][11]. - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [12].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nutex Health Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 21, 2025 [3]. Group 1: Allegations Against Nutex - The complaint alleges that Nutex and its executives made false or misleading statements and failed to disclose critical information regarding their financial practices and relationships with third parties [5]. - Specific allegations include that Nutex engaged in a fraudulent scheme with HaloMD to defraud insurance companies, leading to unsustainable revenue claims [5]. - The company is accused of overstating its ability to remediate internal control weaknesses, which resulted in improper accounting for stock-based compensation obligations [5]. Group 2: Market Reaction - Following the release of a short report by Blue Orca Capital, Nutex's stock price fell by $11.18 per share, or 10.05%, closing at $100.01 on July 22, 2025 [7]. - After Nutex announced a delay in filing its Form 10-Q due to accounting adjustments, its stock price dropped further by $18.22 per share, or 16.39%, closing at $92.91 on August 15, 2025 [8]. Group 3: Legal Proceedings - Investors who purchased Nutex securities between August 8, 2024, and August 15, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Nutex's conduct [10].